Incyte (INCY) Income from Non-Controlling Interests (2019 - 2021)
Incyte (INCY) posted Income from Non-Controlling Interests of -$400000.0 for Q4 2021, down 200.0% on a QoQ basis from $400000.0 in Q3 2021, and down 233.33% year-over-year from $300000.0 in Q4 2020.
Incyte (INCY) Income from Non-Controlling Interests (2019 - 2021) Analysis & Trends
Incyte's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$400000.0 for Q4 2021.
- Quarterly Income from Non-Controlling Interests fell 233.33% year-over-year to -$400000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $600000.0 (down 50.0% YoY) and the FY2021 annual result came in at $600000.0, down 50.0% from the prior year.
- Income from Non-Controlling Interests was -$400000.0 for Q4 2021 at Incyte, down from $400000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $400000.0 in Q3 2021 and bottomed at -$400000.0 in Q4 2021.
- A 3-year average of $200000.0 and a median of $300000.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests soared 400.0% — and 2021, when it plunged 233.33%.
- Incyte's Income from Non-Controlling Interests stood at -$100000.0 in 2019, then surged by 400.0% to $300000.0 in 2020, then plunged by 233.33% to -$400000.0 in 2021.
- Business Quant data shows INCY's Income from Non-Controlling Interests at -$400000.0 in Q4 2021, $400000.0 in Q3 2021, and $300000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -400,000.00 |
| Sep 30, 2021 | 400,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 300,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 300,000.00 |
| Mar 31, 2020 | 300,000.00 |
| Dec 31, 2019 | -100,000.00 |
| Sep 30, 2019 | 300,000.00 |